جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

1 مُخرَج نتائج البحث عن «Atypia»

مقالمفتوح (مستودع)20191استشهاد

Relation of autophagy to apoptosis and progesterone receptor expression in endometrial carcinoma type I

Egyptian Journal of Pathology · مجلد 39 (1) · 165-165

Background The incidence of endometrial carcinoma among Egyptian women has increased in the past few years. This work was performed to evaluate the role of autophagy marker Beclin-1 in endometrial carcinoma type I and correlate it with progesterone receptor (PR) and Bcl-2 expression. Materials and methods This retrospective study included 30 cases of endometrial carcinoma type I, eight cases of endometrial hyperplasia with atypia, and seven cases of endometrial hyperplasia without atypia. Cases were collected from archives of Pathology Department and Early Cancer Detection Unit, Faculty of Medicine, Benha University, through the years 2011 to 2017. Beclin-1, Bcl-2, and PR immunohistochemichal staining was performed on all cases, and the patterns of expression were analyzed. Results Beclin-1 was expressed in 36.7, 62.5, and 71.5% of endometrial carcinoma, endometrial hyperplasia with atypia, and hyperplasia without atypia, respectively. This showed a statistically significant difference (P<0.05). Bcl-2 expression was positive in 53.3, 25, and 14.5% of endometrial carcinoma, endometrial hyperplasia with atypia, and hyperplasia without atypia, respectively, with statistically significant difference (P<0.05). Positive PR immunoreactivity was reported in 40% of endometrial carcinomas, 75% of endometrial hyperplasia with atypia, and 85.5% of hyperplasia without atypia (P<0.05). Both Beclin-1 and PR expressions were significantly increased in correlation with decreased Bcl-2 expression in carcinoma cases (P<0.01). Conclusion Combined estimation of PR and Beclin-1 is a good prognostic marker for endometrial carcinoma type 1. Combination of progestins with proautophagic substances could be used in resistant cases to improve results of treatment.

autophagyBeclin-1apoptosisBcl-2